Enhertu May Further Improve Survival Versus Xeloda Regimens in HER2-Positive Breast Cancer
Patients with advanced HER2-positive unresectable and/or metastatic breast cancer who were previously treated had a 34% reduction in death and a 13-month average increase in survival when treated with Enhertu (fam-trastuzumab-deruxtecan-nxki) versus a Xeloda (capecitabine)-based regimen, according to recent trial results. ARTICLE
Alzheimer's: Brain protein offers clues about higher risk in older women
Although anyone can develop Alzheimer’s disease (AD), a type of dementia associated with cognitive decline and memory loss, previous research has shown that females are more likelyTrusted Source to have the condition than men. In fact, in the United States, almost two-thirds of Alzheimer’s cases are women. ARTICLE
Targeted therapy shows benefit for people with advanced breast cancer in late-stage trial
An experimental treatment shows promise for people with the most common form of advanced-stage breast cancer, according to results from a Phase 3 clinical trial. The details of the trial were presented Thursday at the San Antonio Breast Cancer Symposium. It showed that AstraZeneca’s capivasertib – in combination with Faslodex (fulvestrant), an endocrine therapy already used to treat advanced breast cancer – gave people a median of 7.2 months without disease progression, compa
Blood tests are best at detecting Alzheimer's disease: Study
An important aspect of this study was that p-tau217 was able to monitor such changes in pathology and cognition at very early stages of the disease process. This finding was replicated in an independent cohort from the USA, Wisconsin Registry for Alzheimer's Prevention (WRAP). ARTICLE
